



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/831,954	06/25/2001	Hubert Jan Jozef Loozen	1998.414US	9900

67706 7590 02/07/2008  
ORGANON USA, INC.  
PATENT DEPARTMENT  
56 LIVINGSTON AVENUE  
ROSELAND, NJ 07068

EXAMINER
----------

CLAYTOR, DEIRDRE RENEE

ART UNIT	PAPER NUMBER
----------	--------------

1617

MAIL DATE	DELIVERY MODE
-----------	---------------

02/07/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

**Application No.**

09/831,954

**Applicant(s)**

LOOZEN ET AL.

**Examiner**

Renee Claytor

**Art Unit**

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 26 October 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1, 7, 8 and 13 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1, 7-8, 13 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Request for Continued Examination***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/26/2007 has been entered.

Claims 1, 7-8 and 13 are pending in the application and are being examined on the merits herein.

### ***Response to Arguments***

Applicants arguments filed on 10/26/2007 have been fully considered and are not found persuasive.

In particular, Applicants assert that the Examiner appears to be uncertain that compounds 2 (in the specification) and compound 5b of Lobacarro et al. are the same. Applicants further argue that one would not have predicted that the C5 homolog (compound 3 in the specification) would possess a different property from the C4 compound.

In response to the above arguments, it is noted that the Examiner does not view compound 2 and compound 5b as being dissimilar. However, the focus of the Office Action was to provide motivation for providing the C5 homolog in place of the C4 homolog of the 5b compound of Lobacarro et al. It is noted that Applicants teach compound 2 to have ER $\alpha$  agonist/ER $\beta$  agonist activity and that Lobaccaro et al. does not specify whether the estrogen receptor is ER $\alpha$  or ER $\beta$  but teaches agonist activity at the estrogen receptor. It was also noted in the previous Office Action that the motivation for providing the C5 homolog in place of the 5b compound of Lobacarro et al. rests on an expectation of similar biological activity due to the close chemical structure of the two compounds, and in particular on similar ER agonist activity and the results shown by Applicants in Table B of their specification actually confirm this assumption, as both the compound 5b and the C5 homolog exhibit ER $\alpha$  agonist activity. Accordingly, it is considered that one of ordinary skill in the art at the time of the invention would have found it obvious to provide the homolog with the expectation of achieving an "estrogenic" compound.

Furthermore, it is noted that Applicants determine the compounds tested in Table B to be ER $\alpha$  or Er $\beta$  agonist or antagonists by assigning them a rating of "(-)" which means that it does not satisfy the ER affinity profile of the present invention, while "(+)" means a compound according to the invention, i.e. an agonist ER $\alpha$  and an antagonist for Er $\beta$ " (see page 13 of specification). Applicants do not teach how they arrived at the determination of agonist or antagonist activity, such as what magnitude of the activity was deemed sufficient to warrant the label of "agonist" or "antagonist", and thus it

cannot be reasonably determined whether the difference in the magnitude of the asserted "agonism" and "antagonism" is of sufficient degree to show unexpected results between the compounds. It is noted that a showing of unexpected results must be based on evidence, not argument or speculation. In re Mayne, 104 F.3d 1339, 1343-44, 41 USPQ2d 1451, 1455-56 (Fed. Cir. 1997).

Regarding Applicants' assertion that the claimed compounds are not obvious over the teachings of Lobaccaro et al. because Lobaccaro et al. is not directed to compounds having ER $\alpha$  agonist and Er $\beta$  antagonist activity, it is noted that, as stated by Applicants, Lobaccaro et al. does not distinguish between ER $\alpha$  and Er $\beta$  receptors, and instead merely teaches binding affinity for a "cytosolic estrogen receptor," and thus the activity of the compounds of Lobaccaro et al. with regards to the individual alpha and beta receptors cannot be determined from the disclosure of Lobaccaro et al, all that is known is that the compound 5b of Lobaccaro et al. is "estrogenic," and thus is an agonist for at least one of the types of estrogen receptors. It is furthermore noted that as the teachings of Lobaccaro et al. render the claimed C5 homolog obvious, the property of such a claimed compound will also be rendered obvious by the prior art teachings, since the properties, namely the receptor binding agonism/antagonism, are inseparable from its composition. Therefore, if the prior art teaches the compound or renders the compound obvious, then the properties are also taught or rendered obvious by the prior art. In re Spada, 911 F.2d 705, 709, 15 USPQ 1655, 1658 (Fed. Cir. 1990). See MPEP 2112.01. The burden is shifted to Applicant to show that the prior art

product does not possess or render obvious the same properties as the instantly claimed product.

Regarding Napolitano et al, Applicants argue that Napolitano et al. is "merely concerned with designing high-affinity probes for estrogen receptor imaging," (see page 11 of Remarks submitted October 26, 2007), and is not concerned with pharmaceutical compositions for treating estrogen deficiency disorders. The Examiner respectfully disagrees. The Examiner notes that Napolitano et al. teaches that the compounds are suitable as radio-pharmaceuticals, as discussed above, and thus teaches providing the compounds as pharmaceutical products. Also, as Napolitano et al. teaches that the compounds have affinity for the estrogen receptor, and thus have estrogenic activity, it is considered that one of ordinary skill in the art would have found it obvious to provide the compounds for the treatment of disorders resulting from the deficiency of estrogenic compounds, as recited in claims 7 and 8, with the expectation of reducing the estrogen deficiency, as discussed above.

Applicants' further argue that Napolitano et al. teaches against lengthening the 11beta alkyl chain, because Napolitano et al. teach that the compound having the ethynyl group has a greater affinity than the compound having the propynyl group. The Examiner notes that Napolitano et al. teaches that the compound having the propynyl group does indeed have estrogen binding affinity, even though this affinity is reduced. Accordingly, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of the length of the alkynyl side-chain provided in the composition, according to the guidance

provided by Napolitano, to provide a compound having a desired binding affinity. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). The mere fact that an 11Beta-estradiol derivative having a longer chain may not bind with as high an affinity as derivatives having an ethynyl or propynyl group is not considered to be a sufficient teaching against providing the longer chain derivatives, as the longer chain derivatives would still be expected to have some, if not the highest, binding affinity.

Due to Applicant's amendments, please see the modified grounds of rejection given below.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 7-8 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over the article entitled "Steroidal Affinity labels of the Estrogen Receptor. 3. Estradiol 11 $\beta$ -n-Alkyl Derivatives Bearing a Terminal Electrophilic Group: Antiestrogenic and Cytotoxic Properties" by Lobaccaro et al, 1997 (of record).

Lobaccaro et al. teaches the development of a new series of steroidal affinity labels of the estrogen receptor, including 11Beta-ethyl (C<sub>2</sub>), 11Beta-butyl (C<sub>4</sub>) and 11Beta-decyl (C<sub>10</sub>) derivatives of estradiol (see abstract, in particular). Lobaccaro et al. teaches the synthesis of compounds having the formula I wherein R<sub>11</sub> is butene or ethene (see compounds 5a-5B, Scheme 1 on page 2218, in particular) and teaches testing of the binding of the butene derivative of estradiol 5b and its binding to the estrogen receptor, as well as its activity as an estrogen agonist (see Tables 1 and 2, in particular). Lobaccaro et al. also refers to the compound 5b as being "estrogenic," i.e., and estrogen agonist (see paragraph bridging pages 2221-2222, in particular). Lobaccaro et al. also generally concludes that for estradiol 11Beta-substituted derivatives, the size of the 11beta alkyl side chain is what affects the estrogenic vs. antiestrogenic activity, rather than the size of the whole substituent or the type of electrophilic group substituted on the side chain (see page 2223, first full paragraph, in particular). Lobaccaro et al. teaches that the compounds having affinity for the estrogen receptor may have use in the treatment of estrogen receptor-containing mammary tumors (see paragraph bridging left and right hand columns, page 2223, in particular), and thus teaches the use of compounds that bind the estrogen receptor in a pharmaceutical composition or for pharmaceutical treatment.



Lobaccaro et al. does not specifically teach the estrogenic compound having the group R<sub>11</sub> that is one of the particular chains that is a pentene, pentane, pentyl group or butene group substituted with a cyclopropyl group, as recited in claims 1, 8, and 13.

However, as the compound 5b of Lobaccaro et al. differs from the instantly recited compounds by only a methylene or ethylene group, that is, Lobaccaro teaches a C<sub>4</sub> chain whereas the instant compounds include C<sub>5</sub> chains, it is considered that the instantly claimed compounds are homologous to the compound of Lobaccaro et al, and thus are expected to have similar properties to the compound as taught by Lobaccaro et al, such as estrogenic activity. Thus it is considered that one of ordinary skill in the art would have found it obvious to provide the C<sub>5</sub> homologs of the Lobaccaro et al. C<sub>4</sub> compound, with the expectation of providing a compound with similar properties. See *In re Wilder*, 563 F.2d 457, 195 USPQ 426 (CCPA 1977).

Furthermore, as Lobaccaro et al. teaches that the length of the 11beta alkyl side chain can effect the estrogenic/antiestrogenic activity, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of length of the 11beta alkyl side chain of the compound, according to the guidance provided by Lobaccaro et al, to provide a composition having desired properties. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

Accordingly, the pharmaceutical composition of claim 1, and the steroid compound of claim 13 are considered to be obvious over the teachings of Lobaccaro et al. Regarding the recitation the compound has "ERalpha agonist activity and ERbeta antagonist activity," as recited in claims 1 and 13, it is respectfully pointed out that the the agonist and/or antagonist activity of a compound is a property thereof, and a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963).

Regarding the methods of claims 7 and 8, Lobaccaro et al. teaches that the estrogen compounds can be used to treat estrogen-receptor containing mammary tumors, as discussed above, and renders obvious providing the compounds as recited in the claims, and thus teaches a method of treating estrogen deficiency disorders (i.e. tumors that can be treated by providing an estrogen, and thus are "estrogen deficient") by providing a therapeutic amount of the compound and inducing either ERalpha agonist or ERbeta antagonist activity, as recited in the claims. It is furthermore noted that that the agonist and/or antagonist activity of a compound is a property thereof, and a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963). Accordingly, the composition and method rendered obvious by the references would, absent evidence to the contrary, meet the limitations pertaining to the ERalpha and ERbeta agonist or antagonist activity used therein.

It is furthermore noted that, as Lobaccaro et al. teaches that the compounds having affinity for the estrogen receptor, it would have been obvious to one of ordinary skill in the art to provide such compounds for the treatment of disorders resulting from the deficiency of such estrogenic compounds, as recited in claims 7 and 8, with the expectation that providing the estrogenic compound would reduce the estrogen deficiency.

Claims 1, 7-8 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over the article entitled "11 $\beta$ -Substituted Estradiol Derivatives. 2. Potential Carbon-11-Iodine-Labeled Probes for the Estrogen Receptor" by Napolitano et al, 1995 (of record.)

Napolitano et al. teaches 11 $\beta$ -substituted derivatives of estradiol including ethynyl and propynyl derivatives (see abstract, in particular). Napolitano teaches that the compounds have high affinity for the estrogen receptor, and provides the affinities for compounds 2a (entry 3) having a propynyl group and entry 11 having an ethene group (see Table 1, in particular). Napolitano et al. teaches that the length of the chain of the 1-alkynyl group at the 11 $\beta$  position affects the binding affinity of the compounds, with the shorter chain having a great affinity (see page 2776, first full paragraph of conclusion section, in particular). Napolitano et al. teaches that the compounds can be used as tumor-imaging radiopharmaceuticals (see first full paragraph of Introduction section, in particular), and thus teaches providing a pharmaceutical composition having the compounds, as recited in claim 1.

Napolitano et al. does not specifically teach the estrogenic compound having the group  $R_{11}$  that selected from one of the particular chains that is a pentene, pentane, pentyl group or butene group substituted with a cyclopropyl group, as recited in claims 1, 8, and 13.

However, as the compounds 2a and entry 11 of Napolitano et al. differs from the instantly recited compounds by only an ethylene group ( $-\text{CH}_2-\text{CH}_2-$ ), that is, Napolitano et al. teaches a C2 or C3 chain whereas the instant compounds include C5 chains, it is considered that the instantly claimed compounds are homologous to the compounds of Napolitano et al, and thus are expected to have similar properties to the compounds as taught by Napolitano et al, such as estrogen receptor binding activity. Thus it is considered that one of ordinary skill in the art would have found it obvious to provide the C5 homologs of the Napolitano et al. C2 or C3 compound, with the expectation of providing a compound with similar properties. See *In re Wilder*, 563 F.2d 457, 195 USPQ 426 (CCPA 1977).

Furthermore, as Napolitano et al. teaches that the length of the 11beta alkynyl side chain can effect the estrogen receptor binding affinity, it is considered that one of ordinary skill in the art at the time the invention was made would have found it obvious to vary and/or optimize the amount of length of the 11beta alkynyl side chain of the compound, according to the guidance provided by Napolitano et al, to provide a

composition having desired properties, such as desired estrogen receptor binding affinities. It is noted that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

Accordingly, the pharmaceutical composition of claim 1, and the steroid compound of claim 13 are considered to be obvious over the teachings of Napolitano et al. Regarding the recitation the compound has "ERalpha agonist activity and ERbeta antagonist activity," as recited in claims 1 and 13, it is respectfully pointed out that the the agonist and/or antagonist activity of a compound is a property thereof, and a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963).

Regarding the methods of claims 7 and 8, Napolitano et al. teaches that the estrogen compounds can be used as radiopharmaceuticals to image tumors, as discussed above, and renders obvious providing the compounds as recited in the claims. It is furthermore noted that Napolitano et al. teaches that the compounds have affinity for the estrogen receptor, and thus have estrogenic activity. Accordingly, it is considered that one of ordinary skill in the art would have been motivated to provide such compounds for the treatment of disorders resulting from the deficiency of such estrogenic compounds, as recited in claims 7 and 8, with the expectation that providing the estrogenic compound would reduce the estrogen deficiency. It is furthermore noted that that the agonist and/or antagonist activity of a compound is a property thereof, and

a product and its properties are inseparable. *In re Papesch*, 315 F.2d 381, 137 USPQ 43 (CCPA 1963). Accordingly, the composition and method rendered obvious by the references would, absent evidence to the contrary, meet the limitations pertaining to the ERalpha and ERbeta agonist or antagonist activity used therein.

### ***Conclusion***

No claims are allowed.

### ***Contact Information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is 571-272-8394. The examiner can normally be reached on M-F 8:00-4:30.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number:  
09/831,954  
Art Unit: 1617

Page 14

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor



SAFEMINT MANNATHUN  
SUPERVISORY PATENT EXAMINER